Skip to main content

Table 3 One-, five- and ten-year RSR % of CML in Lithuania

From: Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000–2013

Population

Calendar Period

2000–2004

2005–2009

2010–2013

2000–2013

RSR

95 % CI

RSR

95 % CI

RSR

95 % CI

RSR

95 % CI

1 year RSR

 All

  0–44 years

0.94

0.83–0.98

0.91

0.78–0.97

0.97

0.82–1.00

0.94

0.88–0.97

  45–64 years

0.72

0.60–0.81

0.89

0.79–0.95

0.94

0.82–0.99

0.84

0.78–0.89

  65–74 years

0.43

0.31–0.54

0.83

0.68–0.92

0.67

0.44–0.84

0.59

0.51–0.67

  75+ years

0.35

0.22–0.49

0.57

0.41–0.71

0.49

0.26–0.69

0.46

0.37–0.55

  Overall

0.61

0.55–0.67

0.81

0.74–0.86

0.81

0.74–0.86

0.72

0.69–0.76

 Male

  0–44 years

0.91

0.73–0.91

0.85

0.64–0.94

0.96

0.72–1.00

0.90

0.81–0.95

  45–64 years

0.70

0.52–0.82

0.90

0.72–0.97

1.00

-

0.84

0.74–0.90

  65–74 years

0.39

0.24–0.53

0.81

0.59–0.93

0.81

0.46–0.96

0.58

0.46–0.68

  75+ years

0.28

0.11–0.48

0.54

0.30–0.75

0.43

0.16–0.70

0.41

0.28–0.54

  Overall

0.58

0.49–0.66

0.79

0.70–0.87

0.85

0.73–0.93

0.71

0.65–0.76

 Female

  0–44 years

0.97

0.78–1.00

1.00

-

1.00

-

0.98

0.89–1.00

  45–64 years

0.75

0.55–0.87

0.89

0.72–0.96

0.89

0.70–0.97

0.84

0.75–0.90

  65–74 years

0.48

0.30–0.64

0.84

0.61–0.95

0.51

0.19–0.77

0.61

0.48–0.72

  75+ years

0.41

0.23–0.59

0.59

0.38–0.76

0.56

0.20–0.84

0.51

0.38–0.62

  Overall

0.65

0.55–0.73

0.82

0.73–0.89

0.80

0.67–0.89

0.74

0.68–0.79

5 year RSR

 All

  0–44 years

0.60

0.46–0.71

0.90

0.76–0.97

-

-

0.77

0.69–0.84

  45–64 years

0.42

0.30–0.54

0.70

0.57–0.81

-

-

0.64

0.55–0.71

  65–74 years

0.16

0.08–0.26

0.52

0.35–0.68

-

-

0.33

0.24–0.42

  75+ years

0.14

0.05–0.29

0.09

0.02–0.22

-

-

0.14

0.07–0.23

  Overall

0.33

0.27–0.40

0.55

0.47–0.63

N/R

N/R

0.49

0.45–0.54

 Male

  0–44 years

0.53

0.34–0.70

0.83

0.61–0.94

-

-

0.74

0.62–0.83

  45–64 years

0.44

0.27–0.61

0.74

0.53–0.89

-

-

0.66

0.53–0.77

  65–74 years

0.14

0.05–0.28

0.50

0.27–0.73

-

-

0.33

0.21–0.46

  75+ years

0.14

0.02–0.39

0.16

0.03–0.45

-

-

0.18

0.07–0.35

  Overall

0.32

0.24–0.41

0.59

0.47–0.70

N/R

N/R

0.51

0.44–0.58

 Female

  0–44 years

0.66

0.46–0.80

1.00

-

-

-

0.82

0.69–0.90

  45–64 years

0.40

0.23–0.58

0.67

0.48–0.81

-

-

0.61

0.49–0.72

  65–74 years

0.18

0.07–0.34

0.53

0.30–0.74

-

-

0.33

0.21–0.46

  75+ years

0.14

0.04–0.34

0.05

0.00–0.21

-

-

0.11

0.04–0.23

  Overall

0.35

0.26–0.44

0.52

0.41–0.63

N/R

N/R

0.48

0.41–0.55

10 year RSR

 All

  0–44 years

0.42

0.29–0.55

-

-

-

-

0.60

0.48–0.70

  45–64 years

0.29

0.18–0.42

-

-

-

-

0.52

0.40–0.63

  65–74 years

0.08

0.03–0.18

-

-

-

-

0.19

0.09–0.32

  75+ years

-

-

-

-

-

-

-

-

  Overall

0.21

0.16–0.27

N/R

N/R

N/R

N/R

0.36

0.31–0.42

 Male

  0–44 years

0.38

0.21–0.56

-

-

-

-

0.58

0.41–0.72

  45–64 years

0.33

0.17–0.52

-

-

-

-

0.53

0.37–0.69

  65–74 years

0.04

0.00–0.18

-

-

-

-

0.11

0.01–0.36

  75+ years

-

-

-

-

-

-

-

-

  Overall

0.21

0.14–0.30

N/R

N/R

N/R

N/R

0.37

0.28–0.46

 Female

  0–44 years

0.46

0.27–0.63

-

-

-

-

0.63

0.45–0.76

  45–64 years

0.25

0.11–0.42

-

-

-

-

0.49

0.32–0.65

  65–74 years

0.13

0.03–0.30

-

-

-

-

0.24

0.12–0.39

  75+ years

-

-

-

-

-

-

-

-

  Overall

0.21

0.14–0.30

N/R

N/R

N/R

N/R

0.36

0.28–0.44